Compare MNY & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | ATNM |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 31.4M |
| IPO Year | 2023 | 2013 |
| Metric | MNY | ATNM |
|---|---|---|
| Price | $0.55 | $1.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | 28.8K | ★ 180.1K |
| Earning Date | 12-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | $19,344.45 |
| Revenue Next Year | $17.49 | N/A |
| P/E Ratio | ★ N/A | $1.96 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.38 | $0.74 |
| 52 Week High | $1.60 | $1.74 |
| Indicator | MNY | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 27.09 | 74.58 |
| Support Level | N/A | $0.97 |
| Resistance Level | $1.52 | N/A |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 51.54 | 96.92 |
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.